IP Library › Granted Patent US 10,584,355
Granted Patent B2
US 10,584,355 · App. 15/339,225 · Granted Mar 10, 2020

Chimpanzee adenoviral vector-based filovirus vaccines

Inventors: Nancy J. Sullivan (Kensington, MD); Gary J Nabel (Washington, DC); Clement Asiedu (Olney, MD); Cheng Cheng (Rockville, MD); Alfredo Nicosia (Rome, IT); Riccardo Cortese (Rome, IT); Virginia Ammendola (Naples, IT); Stefano Colloca (Rome, IT)
Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES; GLAXOSMITHKLINE BIOLOGICALS SA
C12N15/86A61K39/12C07K14/005C12N7/00A61K2039/5254A61K2039/5256A61K2039/545C12N2710/10343C12N2760/14134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,584,355
App. No.
15/339,225
Granted
Mar 10, 2020
Kind
B2
Abstract

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Claims (25)

1. An isolated nucleic acid molecule, wherein the isolated nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

2. The isolated nucleic acid molecule of claim 1 , comprising an expression cassette comprising a CMV promoter operably linked to a polynucleotide sequence encoding a filovirus antigenic protein.

3. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:1.

4. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:2.

5. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:3.

6. The isolated nucleic acid molecule of claim 3 , further comprising a promoter operably linked to said nucleic acid molecule.

7. The isolated nucleic acid molecule of claim 4 , further comprising a promoter operably linked to said nucleic acid molecule.

8. The isolated nucleic acid molecule of claim 5 , further comprising a promoter operably linked to said nucleic acid molecule.

9. A composition, comprising:

the isolated nucleic acid molecule of claim 3 ; and

a pharmaceutically acceptable carrier.

10. A composition, comprising:

the isolated nucleic acid molecule of claim 4 ; and

a pharmaceutically acceptable carrier.

11. A composition, comprising:

the isolated nucleic acid molecule of claim 5 ; and

a pharmaceutically acceptable carrier.

12. The isolated nucleic acid molecule of claim 6 , wherein the promoter is a CMV promoter.

13. The isolated nucleic acid molecule of claim 7 , wherein the promoter is a CMV promoter.

14. The isolated nucleic acid molecule of claim 8 , wherein the promoter is a CMV promoter.

15. A composition, comprising:

the isolated nucleic acid of claim 1 contained in a viral particle and a pharmaceutically acceptable carrier.

16. A composition, comprising:

the isolated nucleic acid molecule of claim 1 ; and

a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2020
From: GLAXOSMITHKLINE BIOLOGICALS SA
To: SABIN VACCINE INSTITUTE
Reel/Frame 053171/0909 →
Continuity (3)
Division 13641655
Provisional Application 61325166 · Apr 16, 2010
Related Publication 20170044571A1 · Feb 16, 2017